medical guideline
首页
中医/中西医结合指南
肿瘤学指南
泌尿外科指南
关于我们
郑重声明
联系我们
首页
肿瘤学指南
检索结果
人体系统
运动
骨肿瘤
软组织肿瘤
骨与软组织肿瘤
硬纤维瘤
骶尾部畸胎瘤
神经
中枢神经系统肿瘤
嗜铬细胞瘤和副神经节瘤
副神经节瘤
胶质细胞瘤
前庭神经鞘瘤
星形胶质细胞瘤和少突胶质细胞瘤
弥漫性胶质瘤
神经纤维瘤
神经细胞瘤
神经内分泌肿瘤
内分泌
甲状腺肿瘤
垂体肿瘤
肾上腺肿瘤
甲状旁腺肿瘤
胸腺肿瘤
神经内分泌肿瘤
循环
心脏肿瘤
淋巴瘤
骨髓瘤
白血病
血液肿瘤
血管瘤
呼吸
肺癌
鼻咽癌
喉部肿瘤
下咽癌
鼻腔和副鼻窦癌
呼吸道肿瘤
鼻颅咽管瘤
淋巴管肌瘤
消化
胰腺肿瘤
口腔癌
肛门癌
口咽癌
胆囊癌
胆管肿瘤
直肠癌
结肠癌
胃癌
小肠癌
肝癌
大肠肿瘤
唾液腺癌
阑尾肿瘤
食管肿瘤
肝肿瘤
壶腹肿瘤
肝胆癌
结直肠肿瘤
食管胃肿瘤
胃肠道肿瘤
消化道肿瘤
泌尿
膀胱肿瘤
肾癌
脐尿管癌
尿路上皮癌
肾血管平滑肌脂肪瘤
泌尿生殖肿瘤
生殖
女性
子宫肿瘤
卵巢肿瘤
乳腺肿瘤
阴道肿瘤
输卵管癌
外阴癌
妊娠滋养细胞肿瘤
妇科肿瘤
男性
前列腺肿瘤
性索间质瘤
睾丸肿瘤
阴茎癌
男性乳腺肿瘤
泌尿生殖肿瘤
其他
症状管理
治疗方案
诊断/检测/评估方法
预防和筛查
COVID-19大流行癌症患者相关指导建议
皮肤肿瘤
黑色素瘤
头颈部肿瘤
康复营养
生育能力
体力活动
心理健康
腹膜肿瘤
实体瘤
胸部肿瘤
长期监测
Cowden综合征
转诊
遗传性癌症综合征
癌症患者其他类问题管理
寡转移性疾病
基因测序
易感基因变异的分类
外科肿瘤
罕见癌症
不明原因癌症
纤维瘤
腹部肿瘤
老年肿瘤
儿童/青少年肿瘤
人类微生物组与癌变
检索结果
按关键字
按标题
按关键词
按摘要
按作者
按期刊
按发表年份
共搜索到
57条
与
Adjuvant
有关的结果
SEOM Clinical Guidelines for Endometrial Cancer (2017)
2018年 发布于
Clin Transl Oncol
20卷 第1期
所属人体系统:
生殖
|
子宫肿瘤
Spanish Society of Medical Oncology
Adjuvant
Treatment
Chemotherapy
Endometrial Cancer
Radiotherapy
指南简介
原文链接
German S3 Guideline for Renal Cell Carcinoma : Presentation and Discussion of Essential Aspects for the Radiation Oncologist
2018年 发布于
Strahlenther Onkol
194卷 第1期
所属人体系统:
泌尿
|
肾癌
无
Purpose: We Aim to Introduce and Discuss the Statements and Recommendations of the German S3 Guideline on Renal Cell Cancer for Daily Practice of Radiation Oncologists
Methods: This Report Comprises Indication
Treatment Decision
Dose Prescription and Current Literature Including Treatment of Oligometastatic Disease
Results: According to Different Stages of the Disease and the Structure of the Guideline We Focus on Five Treatment Situations and Recommendations for Decision Making: (1) Neo-/adjuvant Treatment Before Or after Nephrectomy: No Indication for Radiotherapy (2) Small Renal Mass: Stereotactic Ablative Radiotherapy Is Currently Seen as Experimental Option due to Small Patient Numbers Reported in the Literature However
Local Tumor Control Achieved by SBRT Appears Favourable with >90% at 2 Years (3) Oligometastasis: Radiation Treatment with Higher Local Doses Or Stereotactic Treatment Is Possible after Interdisciplinary Discussion Indications for Palliative (4) and Symptomatic Treatment (5) Are Not Different Compared to Other Tumor Entities
Conclusion: Currently
There Is No Evidence-based Indication for Radiation Treatment in the Primary Setting (adjuvant/neoadjuvant Or Definitive) of Renal Cell Cancer in the Future Stereotactic Radiotherapy Should Have a Stronger Role in the Treatment of Medically Inoperable Patients with Primary Renal Cell Cancer and Especially in the Setting of Oligometastasis
指南简介
原文链接
New: S3-Guideline of Endometrial Cancer
2018年 发布于
Geburtshilfe Frauenheilkd
78卷 第10期
所属人体系统:
生殖
|
子宫肿瘤
The Gynaecological Oncology Working Group
Adjuvant
Therapy
Chemotherapy
Endometrial Cancer
Radiotherapy
Recurrence
指南简介
原文链接
Tumour Profiling Tests to Guide Adjuvant Chemotherapy Decisions in Early Breast Cancer
2018年 发布于
National Institute for Health and Care Excellence
卷 第期
所属人体系统:
生殖
|
乳腺肿瘤
National Institute for Health and Care Excellence
Breast Cancer
treatment
adjuvant Chemotherapy
Tumour Profiling Test
指南简介
原文链接
Adjuvant Endocrine Therapy for Women with Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
2018年 发布于
American Society of Clinical Oncology
卷 第期
所属人体系统:
生殖
|
乳腺肿瘤
American Society of Clinical Oncology
Breast Neoplasms
Hormone Replacement Therapy
Adjuvant
Endocrine Therapy
Aromatase Inhibitor
指南简介
原文链接
An Italian Delphi Study to Evaluate Consensus on Adjuvant Endocrine Therapy in Premenopausal Patients with Breast Cancer: the ERA Project 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 11 Medical and Health Sciences 1103 Clinical Sciences
2018年 发布于
BMC Cancer
18卷 第932期
所属人体系统:
生殖
|
乳腺肿瘤
无
Adjuvant
Endocrine Therapy
Aromatase Inhibitor
Breast Cancer
LHRHa
Ovarian Function Suppression
Premenopausal Patients
Tamoxifen
指南简介
原文链接
SEOM Clinical Guideline for the Management of Malignant Melanoma (2017)
2018年 发布于
Clin Transl Oncol
20卷 第1期
所属人体系统:
其他
|
黑色素瘤
Spanish Society of Medical Oncology
Melanoma
Metastatic
Adjuvant
Immunotherapy
B-RAF
指南简介
原文链接
Dabrafenib with Trametinib for Adjuvant Treatment of Resected BRAF V600 Mutation-positive Melanoma
2018年 发布于
National Institute for Health and Care Excellence
卷 第期
所属人体系统:
其他
|
黑色素瘤
National Institute for Health and Care Excellence
Melanoma
BRAF V600
Dabrafenib
adjuvant
指南简介
原文链接
Adjuvant Endocrine Therapy in Premenopausal Patients with Hormone Receptor-positive Early Breast Cancer: Evidence Evaluation and GRADE Recommendations by the Italian Association of Medical Oncology (AIOM)
2018年 发布于
Eur J Cancer
99卷 第期
所属人体系统:
生殖
|
乳腺肿瘤
The Italian Association of Medical Oncology
AIOM Guidelines
Adjuvant
Endocrine Therapy
Breast Cancer
GRADE Methodology
Premenopausal Women
指南简介
原文链接
Practical Consensus Recommendations Regarding the Management of HER2 Neu Positive Early Breast Cancer
2018年 发布于
South Asian J Cancerv
7卷 第2期
所属人体系统:
生殖
|
乳腺肿瘤
无
Adjuvant
Trastuzumab
TCH Regimen
Double Agent
Tumor Size
指南简介
原文链接
French CcAFU Guidelines - Update 2018-2020: Adrenal Cancer
2018年 发布于
Prog Urol
28卷 第Suppl 1期
所属人体系统:
内分泌
|
肾上腺肿瘤
Cancer Committee of the Association Française D'Urologie
Adjuvant
Treatments
Adrenal Metastasis
Adrenocortical Carcinoma
Carcinome Corticosurrénalien
Chirurgie
Malignant Pheochromocytoma
Métastase Surrénalienne
Phéochromocytome Malin
Surgery
Traitements
Adjuvant
s
指南简介
原文链接
Duration of Oxaliplatin-containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline
2019年 发布于
American Society of Clinical Oncology
卷 第期
所属人体系统:
消化
|
结直肠肿瘤
American Society of Clinical Oncology
Colon Cancer
Stage III
Oxaliplatin
Adjuvant
Therapy
指南简介
原文链接
Diagnostic Value of Imaging (ultrasonography, Doppler, CT, MR, PET-CT) for the Diagnosis of a Suspicious Ovarian Mass and Staging of Ovarian, Tubal Or Primary Peritoneal Cancer: Article Drafted from the French Guidelines in Oncology Entitled `Initial Man
2019年 发布于
Gynecol Obstet Fertil Senol
47卷 第2期
所属人体系统:
生殖
|
输卵管癌
FRANCOGYN (Groupe Français De Recherche En Chirurgie Oncologique Et Gynécologique)
Au CNGOF (Collège National Des Gynécologues Obstétriciens Français)
À La SFOG (Société Française D’oncologie Gynécologique Et Au Groupe GINECO-ARCAGY (Groupe D’investigateurs Nationaux Pour L’étude Des Cancers Ovariens Et Du Sein – Association De Recherche Sur Les Cancers Dont Gynécologiques) Et Sont Labellisées Par L’INCa (Institut National Du Cancer).
Transvaginal Ultrasound Is the First-line Examination Allowing Characterizing 80 to 90% of Adnexal Masses (LP1). If Performed by an Expert
a Subjective Analysis Is Optimal. If Performed by a Non-expert
Combining the Use of Simple Rules with Subjective Analysis Can Achieve the Diagnostic Performance of an Expert (LP1). Whichever the Chosen Model (subjective Analysis by an Expert Or Combination of the Simple Rules with a Subjective Analysis by a Non-expert)
a Second-line Examination Will Have to Be Proposed in the Complex Or Indeterminate Cases (about 20% of the Masses) (grade A). the Best-performing Second-line Test for Characterization Is Pelvic MRI (LP1). If Read by an Expert
a Pathological Hypothesis Can Or Should Be Suggested (grade D). in Case of Non-expert Reading
the Use of the ADNEXMR Score Allows a Reliable Assessment of the Positive Predictive Value of Malignancy to Guide the Patient Towards the Best Management (gradeC). for Preoperative Assessment and Evaluation of Resectability of Ovarian
Fallopian Tube Or Primary Peritoneal Cancer
It Is Recommended to Perform a Chest Abdomen and Pelvis CT with Contrast Agent Injection (LP2
Grade B). in the Event of a Contraindication to the Injection of Iodinated Contrast Agent (severe Renal Insufficiency
GFR <30mL/min)
an Abdomen and Pelvis MRI Completed with a Non-injected Chest CT May Be Proposed (LP3
Grade C). by Analogy
the Same Examinations Are Recommended to Evaluate the Disease after Neo-adjuvant Chemotherapy (LP3
Recommendation Grade C). Further Studies Will Be Required to Determine Whether PET-CT Provides Better Lymph Node Assessment Before Retroperitoneal and Pelvic Lymphadenectomy. PET-CT May Be Used to Eliminate Lymph Node Involvement in the Absence of Suspicious Lymph Nodes on Morphological Examination (LP3
Grade C). the Report Should Specify the Localizations Leading to a Risk of Incomplete Cytoreductive Surgery and Lesions Outside the Field Explored During Surgery.
指南简介
原文链接
Management of Epithelial Cancer of the Ovary, Fallopian Tube, and Primary Peritoneum. Short Text of the French Clinical Practice Guidelines Issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and Endorsed by INCa
2019年 发布于
Eur J Obstet Gynecol Reprod Biol
236卷 第_期
所属人体系统:
生殖
|
输卵管癌
FRANçais De Recherche En Chirurgie Oncologique Et GYNécologique (FRANCOGYN)
Le Collège National Des Gynécologues Et Obstétriciens Français (CNGOF)
La Société Française D’oncologie Gynécologique (SFOG) Et Le Groupe D’investigateurs National Des Études Des Cancers Ovariens Et Du Sein (GINECO-ARCAGY) Et De L’institut National Du Cancer (INCa)
An MRI Is Recommended for an Ovarian Mass That Is Indeterminate on Ultrasound. the ROMA Score (combining CA125 and HE4) Can Also Be Calculated (Grade A). in Presumed Early-stage Ovarian Or Tubal Cancers
the Following Procedures Should Be Performed: an Omentectomy (at a Minimum
Infracolic)
an Appendectomy
Multiple Peritoneal Biopsies
Peritoneal Cytology (grade C)
and Pelvic and Para-aortic Lymphadenectomies (Grade B) for All Histologic Types
Except the Expansile Mucinous Subtypes
for Which Lymphadenectomies Can Be Omitted (grade C). Minimally Invasive Surgery Is Recommended for Early-stage Ovarian Cancer
When There Is No Risk of Tumor Rupture (grade B).
Adjuvant
Chemotherapy by Carboplatin and Paclitaxel Is Recommended for All High-grade Ovarian and Tubal Cancers (FIGO Stages I-IIA) (grade A). for FIGO Stage III Or IV Ovarian
Tubal
and Primary Peritoneal Cancers
a Contrast-enhanced Computed Tomography (CT) Scan of the Thorax/abdomen/pelvis Is Recommended (Grade B)
as Well as Laparoscopic Exploration to Take Multiple Biopsies (grade A) and a Carcinomatosis Score (Fagotti Score at a Minimum) (grade C) to Assess the Possibility of Complete Surgery (i.e.
Leaving No Macroscopic Tumor Residue). Complete Surgery by a Midline Laparotomy Is Recommended for Advanced Ovarian
Tubal
Or Primary Peritoneal Cancers (grade B). for Advanced Cancers
Para-aortic and Pelvic Lymphadenectomies Are Recommended When Metastatic Adenopathy Is Clinically Or Radiologically Suspected (grade B). When Adenopathy Is Not Suspected and When Complete Peritoneal Surgery Is Performed as the Initial Surgery for Advanced Cancer
the Lymphadenectomies Can Be Omitted Because They Do Not Modify Either the Medical Treatment Or Overall Survival (grade B). Primary Surgery (before Other Treatment) Is Recommended Whenever It Appears Possible to Leave No Tumor Residue (grade B). after Primary Surgery Is Complete
6 Cycles of Intravenous Chemotherapy (grade A) Are Recommended
Or a Discussion with the Patient About Intraperitoneal Chemotherapy
According to Her Risk-benefit Ratio. after Complete Interval Surgery for FIGO Stage III Disease
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Can Be Proposed
in Accordance with the Modalities of the OV-HIPEC Trial (grade B). in Cases of Postoperative Tumor Residue Or in FIGO Stage IV Tumors
Chemotherapy Associated with Bevacizumab Is Recommended (grade A).
指南简介
原文链接
Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update
2019年 发布于
American Society of Clinical Oncology
卷 第期
所属人体系统:
消化
|
胰腺肿瘤
American Society of Clinical Oncology
Pancreatic Adenocarcinoma
Curable
adjuvant Chemotherapy
指南简介
原文链接
Report from the 20th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28-29 September 2018
2019年 发布于
Curr Oncol
26卷 第6期
所属人体系统:
消化
|
结直肠肿瘤
无
Colorectal Cancer
Adjuvant
Radiation Therapy
Biomarkers
Cytoreductive Surgery
Hipec
Local Excision
Molecular Tests
Rectal Cancer
Sidedness
Surgery
Surveillance
Total Neoadjuvant Treatment
指南简介
原文链接
ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease
2019年 发布于
Int J Gynecol Cancer
29卷 第_期
所属人体系统:
生殖
|
卵巢肿瘤
European Society for Medical Oncology
European Society of Gynaecologic Oncology Ovarian Cancer Consensus Conference Working Group
Adjuvant
Treatment
Molecular Biology
Ovarian Cancer
Pathology
Recurrent Disease
Surgery
指南简介
原文链接
Diagnostic Value of Imaging (ultrasonography, Doppler, CT, MR, PET-CT) for the Diagnosis of a Suspicious Ovarian Mass and Staging of Ovarian, Tubal Or Primary Peritoneal Cancer: Article Drafted from the French Guidelines in Oncology Entitled `Initial Man
2019年 发布于
Gynecol Obstet Fertil Senol
47卷 第2期
所属人体系统:
生殖
|
卵巢肿瘤
FRANCOGYN (Groupe Français De Recherche En Chirurgie Oncologique Et Gynécologique)
Au CNGOF (Collège National Des Gynécologues Obstétriciens Français)
À La SFOG (Société Française D’oncologie Gynécologique Et Au Groupe GINECO-ARCAGY (Groupe D’investigateurs Nationaux Pour L’étude Des Cancers Ovariens Et Du Sein – Association De Recherche Sur Les Cancers Dont Gynécologiques) Et Sont Labellisées Par L’INCa (Institut National Du Cancer).
Transvaginal Ultrasound Is the First-line Examination Allowing Characterizing 80 to 90% of Adnexal Masses (LP1). If Performed by an Expert
a Subjective Analysis Is Optimal. If Performed by a Non-expert
Combining the Use of Simple Rules with Subjective Analysis Can Achieve the Diagnostic Performance of an Expert (LP1). Whichever the Chosen Model (subjective Analysis by an Expert Or Combination of the Simple Rules with a Subjective Analysis by a Non-expert)
a Second-line Examination Will Have to Be Proposed in the Complex Or Indeterminate Cases (about 20% of the Masses) (grade A). the Best-performing Second-line Test for Characterization Is Pelvic MRI (LP1). If Read by an Expert
a Pathological Hypothesis Can Or Should Be Suggested (grade D). in Case of Non-expert Reading
the Use of the ADNEXMR Score Allows a Reliable Assessment of the Positive Predictive Value of Malignancy to Guide the Patient Towards the Best Management (gradeC). for Preoperative Assessment and Evaluation of Resectability of Ovarian
Fallopian Tube Or Primary Peritoneal Cancer
It Is Recommended to Perform a Chest Abdomen and Pelvis CT with Contrast Agent Injection (LP2
Grade B). in the Event of a Contraindication to the Injection of Iodinated Contrast Agent (severe Renal Insufficiency
GFR <30mL/min)
an Abdomen and Pelvis MRI Completed with a Non-injected Chest CT May Be Proposed (LP3
Grade C). by Analogy
the Same Examinations Are Recommended to Evaluate the Disease after Neo-adjuvant Chemotherapy (LP3
Recommendation Grade C). Further Studies Will Be Required to Determine Whether PET-CT Provides Better Lymph Node Assessment Before Retroperitoneal and Pelvic Lymphadenectomy. PET-CT May Be Used to Eliminate Lymph Node Involvement in the Absence of Suspicious Lymph Nodes on Morphological Examination (LP3
Grade C). the Report Should Specify the Localizations Leading to a Risk of Incomplete Cytoreductive Surgery and Lesions Outside the Field Explored During Surgery.
指南简介
原文链接
Management of Epithelial Cancer of the Ovary, Fallopian Tube, and Primary Peritoneum. Short Text of the French Clinical Practice Guidelines Issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and Endorsed by INCa
2019年 发布于
Eur J Obstet Gynecol Reprod Biol
236卷 第_期
所属人体系统:
生殖
|
卵巢肿瘤
FRANçais De Recherche En Chirurgie Oncologique Et GYNécologique (FRANCOGYN)
Le Collège National Des Gynécologues Et Obstétriciens Français (CNGOF)
La Société Française D’oncologie Gynécologique (SFOG) Et Le Groupe D’investigateurs National Des Études Des Cancers Ovariens Et Du Sein (GINECO-ARCAGY) Et De L’institut National Du Cancer (INCa)
An MRI Is Recommended for an Ovarian Mass That Is Indeterminate on Ultrasound. the ROMA Score (combining CA125 and HE4) Can Also Be Calculated (Grade A). in Presumed Early-stage Ovarian Or Tubal Cancers
the Following Procedures Should Be Performed: an Omentectomy (at a Minimum
Infracolic)
an Appendectomy
Multiple Peritoneal Biopsies
Peritoneal Cytology (grade C)
and Pelvic and Para-aortic Lymphadenectomies (Grade B) for All Histologic Types
Except the Expansile Mucinous Subtypes
for Which Lymphadenectomies Can Be Omitted (grade C). Minimally Invasive Surgery Is Recommended for Early-stage Ovarian Cancer
When There Is No Risk of Tumor Rupture (grade B).
Adjuvant
Chemotherapy by Carboplatin and Paclitaxel Is Recommended for All High-grade Ovarian and Tubal Cancers (FIGO Stages I-IIA) (grade A). for FIGO Stage III Or IV Ovarian
Tubal
and Primary Peritoneal Cancers
a Contrast-enhanced Computed Tomography (CT) Scan of the Thorax/abdomen/pelvis Is Recommended (Grade B)
as Well as Laparoscopic Exploration to Take Multiple Biopsies (grade A) and a Carcinomatosis Score (Fagotti Score at a Minimum) (grade C) to Assess the Possibility of Complete Surgery (i.e.
Leaving No Macroscopic Tumor Residue). Complete Surgery by a Midline Laparotomy Is Recommended for Advanced Ovarian
Tubal
Or Primary Peritoneal Cancers (grade B). for Advanced Cancers
Para-aortic and Pelvic Lymphadenectomies Are Recommended When Metastatic Adenopathy Is Clinically Or Radiologically Suspected (grade B). When Adenopathy Is Not Suspected and When Complete Peritoneal Surgery Is Performed as the Initial Surgery for Advanced Cancer
the Lymphadenectomies Can Be Omitted Because They Do Not Modify Either the Medical Treatment Or Overall Survival (grade B). Primary Surgery (before Other Treatment) Is Recommended Whenever It Appears Possible to Leave No Tumor Residue (grade B). after Primary Surgery Is Complete
6 Cycles of Intravenous Chemotherapy (grade A) Are Recommended
Or a Discussion with the Patient About Intraperitoneal Chemotherapy
According to Her Risk-benefit Ratio. after Complete Interval Surgery for FIGO Stage III Disease
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Can Be Proposed
in Accordance with the Modalities of the OV-HIPEC Trial (grade B). in Cases of Postoperative Tumor Residue Or in FIGO Stage IV Tumors
Chemotherapy Associated with Bevacizumab Is Recommended (grade A).
指南简介
原文链接
Neoadjuvant Systemic Therapy in Melanoma: Recommendations of the International Neoadjuvant Melanoma Consortium
2019年 发布于
Lancet Oncol
20卷 第7期
所属人体系统:
其他
|
黑色素瘤
International Neoadjuvant Melanoma Consortium
Melanoma
Neoadjuvant Therapy
Recommendation
指南简介
原文链接
首页
1
2
3
下一页
尾页
共57条,每页显示
20条
50条
100条
跳转至第
页
确定